Search
Protagonist Therapeutics Inc
PTGXAdd to Watchlist
114.230USD
+2.790+2.50%
Market hours （ET）Quotes delayed by 15 min
7.34BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-17The current earnings forecast score of Protagonist Therapeutics Inc is 8.57, ranking 99 out of 388 in the Biotechnology & Medical Research industry. The average price target is 91.00, with a high of 115.00 and a low of 65.00.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
118.923
Target Price
+7.49%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Protagonist Therapeutics Inc
PTGX
14
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Protagonist Therapeutics Inc's expected revenue for the next quarter?
Protagonist Therapeutics Inc's expected revenue is 213.37M.
What is Protagonist Therapeutics Inc's price target?
Analysts forecast that Protagonist Therapeutics Inc's price target is USD 91.00, with the highest forecast at USD 115.00 and the lowest forecast at USD 65.00.
How have Protagonist Therapeutics IncPTGX's recent earnings per share performed?
The market expectation was USD 0.06, while Protagonist Therapeutics IncPTGX's earnings per share (EPS) for the previous quarter was USD -0.69. EPS for the next quarter is expected at USD 1.94.
What is the analyst rating for Protagonist Therapeutics Inc?
Based on the ratings of Protagonist Therapeutics Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
